Form 3 Filing by Chemomab Therapeutics Ltd. Officer

This filing is a Form 3, which reports initial beneficial ownership of securities, by George Adi Mor, Chief Executive Officer and Director of Chemomab Therapeutics Ltd. The filing details holdings of American Depositary Shares (ADS) both directly and indirectly, including those held by his spouse. It also outlines various stock options and restricted stock units (RSUs) granted to Mr. Mor and his spouse, specifying their vesting schedules and exercise details. The filing was made between March 18, 2026, and April 20, 2026, under temporary relief for foreign private issuers. Direct holdings include 79,268 ADSs, with additional direct holdings of 31,712 ADSs in RSUs vesting by October 1, 2028, and 18,750 ADSs in RSUs vesting by April 10, 2029. Indirect holdings, through his spouse, amount to 50,059 ADSs. Derivative holdings include stock options to purchase 32,925 ADSs with an exercise price of $5.94, 109,718 ADSs with an exercise price of $5.16, and 8,431 ADSs with an exercise price of $3.20, some of which are held by his spouse.